Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555589 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
A Phase 3 study of Neurotrophic Keratopathy, sponsored by ReGenTree.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT05555589 is a Phase 3 study of Neurotrophic Keratopathy that is actively recruiting participants, run by ReGenTree. The registered enrollment target is 70 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT05555589, a Phase 3 study of Neurotrophic Keratopathy, is actively recruiting participants, sponsored by ReGenTree.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RGN-259
Study Locations (20)
Florida
- Nature Coast Clinical Research - Crystal River
- University of Miami - Bascom Palmer Eye Institute, Miami - Miami
- University of South Florida, Ophthalmolgoy - Tampa
North Carolina
- Duke Eye Center - Durham
- Oculus Research - Raleigh
- CORE, Inc. / Vita Eye Clinic - Shelby
California
- Harvard Eye Associates - Laguna Hills
- Loma Linda University Eye Institute - Loma Linda
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
- Advance Vision Research Institute - Longmont
Missouri
- Midwest Vision Research Foundation - Chesterfield
- Washington University Eye Center - St Louis
Connecticut
- Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons - Danbury
Georgia
- Thomas Eye Group, P.C. - Sandy Springs
Illinois
- Northwestern - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555589
The ClinicalTrials.gov registry entry for NCT05555589 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReGenTree, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurotrophic Keratopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05555589 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT05555589 about?
NCT05555589 is a clinical study titled "Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2". The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
What is the current status of trial NCT05555589?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2023-04-11. Estimated completion is 2026-05-30.
What conditions does trial NCT05555589 study?
This clinical trial studies the following conditions: Neurotrophic Keratopathy.
What interventions are being tested in trial NCT05555589?
The interventions under investigation include: Placebo (DRUG), RGN-259 (DRUG).
Who is sponsoring clinical trial NCT05555589?
This trial is sponsored by ReGenTree, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555589 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.